Saturday 17 October 2026
Export PRFX’s income statement to Excel — free account
PainReform Ltd.
PRFX Healthcare Drug Manufacturers Specialty & Generic
PainReform Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17,000.00.
0.81
0.04
−4.71%
Follow PRFX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 1,209.00 | 348.00 | 102.00 | 54.66 | 2.16 | 3.06 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 2,355.00 | 2,352.00 | 522.00 | 792.30 | 89.40 | 33.25 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 3 | 2 | 4 | 6 | 7 | 6 | 7 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | ||||
| Gross margin, % | — | — | — | 0.00 | — | 0.00 | 0.00 | — | — | (311.76) | |||||
| EBT | — | — | (1) | (1) | (4) | (7) | (9) | (9) | (15) | (5) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (29,494.12) | |||||
| Net income | — | 0 | (1) | (1) | (4) | (7) | (9) | (9) | (15) | (5) | |||||
| Depreciation | — | — | — | 0 | — | 0 | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | ||||
| Earnings | — | — | (2.01) | (2,659.43) | (1,499.70) | (887.82) | (983.80) | (315.65) | (105.52) | (7.47) | |||||
| Cash flow | — | — | (0.68) | (1,218.00) | (947.04) | (799.15) | (717.67) | (225.64) | (91.26) | (6.10) | |||||
| Capex | — | — | 0.00 | 0.00 | (3.70) | (6.10) | (0.67) | (0.30) | (0.09) | 0.00 | |||||
| Free cash flow | — | — | (0.68) | (1,218.00) | (950.74) | (805.24) | (718.33) | (225.95) | (91.35) | (6.11) | |||||
| Book value | — | — | (4.79) | (11,244.00) | 6,155.56 | 2,205.12 | 1,224.56 | 244.56 | 13.19 | 14.34 | |||||
| Shares, m | — | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 0.01 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | 0.20 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (1) | (3) | (7) | (6) | (7) | (13) | (4) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | (1) | (1) | (3) | (7) | (6) | (7) | (13) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 0 | (5) | 17 | 18 | 11 | 7 | 2 | 2 | ||||
| Total debt | — | — | 5 | 6 | — | — | — | — | — | — | |||||
| Net debt | — | — | 4 | 5 | (16) | (17) | (10) | (8) | (4) | (4) | |||||
| Shareholders’ equity | — | — | (4) | (6) | 17 | 18 | 11 | 7 | 2 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (4,627.16) | (205.46) | (42.74) | (39.30) | (56.00) | (83.96) | (201.84) | (60.79) | ||||
| ROIC | — | — | 0.00 | 0.00 | (112.30) | (298.15) | (667.85) | 0.00 | 0.00 | (62.48) | |||||
| ROE | — | — | 16.07 | 10.97 | (185.20) | (41.76) | (60.42) | (102.34) | (321.92) | (90.37) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
PainReform Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. | $5.5M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.6M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| RDHL Redhill Biopharma Ltd. | $4.4M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| YCBD cbdMD, Inc. | $4.0M | 41.2× | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| IMCC IM Cannabis Corp. | $2.2M | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | Compare |
| NEPTF Neptune Wellness Solutions Inc. | $1.6M | — (loss-making) | — (loss-making) | −37.75% (below 0%: shrinking) | n/m | +53.44% (above 0%: growing) | 13.62% | (232.88%) | Compare |
| Median of peers | $3.7M | — | — | −8.60% | — | −2.68% | 19.83% | (20.36%) |
PainReform Ltd. (PRFX) key facts
- PainReform Ltd. (PRFX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- PainReform Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17,000.00.
- As of October 16, 2026, PRFX traded at $0.81, a market capitalization of $2.6 million.
- Return on equity was −90.4% and debt-to-equity 0.00.
- Its Altman Z-score is −7.91 (distress zone) for fiscal 2025.